{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:50Z","timestamp":1791333410535,"version":"4.3.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) are a novel class of antineoplastic treatment that enhances immunity against tumors. They are associated with immune adverse events, and several neurological syndromes have been described, including multiple sclerosis and atypical demyelination. We performed a systematic literature review of case reports with neurological immune adverse events that presented with central nervous system demyelination, up to December 2019. We found 23 cases: seven with myelitis, four isolated optic neuritis, one neuromyelitis optica spectrum disorder, five multiple sclerosis, and six with atypical demyelination. Ipilimumab was the most frequently used ICI (11\/23). The median time to develop symptoms from the onset of ICI was 6.5 weeks [range 1.0\u201343.0], and from last ICI dose was 14 days [range 0\u2013161]. Anatomopathological examination was performed in four cases, with the finding of a T-cell mediated immune response. Outcomes were generally favorable after immunosuppression: 18 patients had improvement or a full recovery, three patients did not respond to treatment, three patients died, and in one, treatment was not reported. We describe the patients' clinical presentation, treatment administered, and outcomes. We further speculate on possible pathophysiological mechanisms and discuss potential treatments that may be worth investigating.<\/jats:p>","DOI":"10.3389\/fneur.2020.538695","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T01:45:37Z","timestamp":1607651137000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Marcos C. B.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo H.","family":"de Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus M.","family":"Simabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"576980","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes","volume":"334","author":"Gill","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neurooncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2548528","article-title":"Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep Neurol Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung","volume":"19","author":"Matsuoka","year":"2018","journal-title":"Clin Lung Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","article-title":"Anti-Hu-associated autoimmune limbic encephalitis in a patient with pd-1 inhibitor-responsive myxoid chondrosarcoma","volume":"23","author":"Papadopoulos","year":"2018","journal-title":"Oncologist."},{"key":"B16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jamaoncol.2019.2304","article-title":"Weakness and myalgia in a patient with hepatocellular carcinoma undergoing checkpoint inhibitor therapy","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"iv25","DOI":"10.1093\/neuonc\/now188.085","article-title":"P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab","volume":"18","author":"G\u00f3mez Vicente","year":"2016","journal-title":"Neuro Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition","volume":"21","year":"2019","journal-title":"Curr Oncol Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMcp053247","article-title":"Optic neuritis","volume":"354","author":"Balcer","year":"2006","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","author":"Group","year":"2002","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/archneur.64.10.1426","article-title":"Acute fulminant demyelinating disease","volume":"64","author":"de Seze","year":"2007","journal-title":"Arch Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13691-019-00367-5","article-title":"Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature","volume":"8","author":"Kubo","year":"2019","journal-title":"Int Cancer Conf J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-019-0803-x","article-title":"Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature","volume":"7","author":"Carausu","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1159\/000368316","article-title":"Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma","volume":"37","author":"O'Kane","year":"2014","journal-title":"Oncol Res Treat."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4379","article-title":"CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy","author":"Kunchok","year":"2019","journal-title":"JAMA Neurol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0393-z","article-title":"Neurologic immune-related adverse events associated with adjuvant ipilimumab: Report of two cases","volume":"6","author":"Garcia","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/WNO.0000000000000217","article-title":"Ipilimumab-associated bilateral optic neuropathy","volume":"35","author":"Yeh","year":"2015","journal-title":"J Neuro Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JOP.19.00438","article-title":"Optic neuritis related to atezolizumab treatment in a patient with metastatic non-small-cell lung cancer","volume":"16","author":"Sengul Samanci","year":"2020","journal-title":"JCO Oncol Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicina54050082","article-title":"Bilateral optic neuritis secondary to nivolumab therapy: a case report","volume":"54","author":"Kartal","year":"2018","journal-title":"Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0170-9","article-title":"Acute visual loss after ipilimumab treatment for metastatic melanoma","volume":"4","author":"Wilson","year":"2016","journal-title":"J Immunother Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00415-019-09562-z","article-title":"Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer","volume":"266","author":"Romeo","year":"2019","journal-title":"J Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/1352458518803724","article-title":"Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma","volume":"25","author":"Dur\u00e3es","year":"2019","journal-title":"Mult Scler J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with nivolumab for melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient","volume":"7","author":"Pillonel","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-associated acute demyelinating encephalitis: a case report and literature review","volume":"17","author":"Zafar","year":"2019","journal-title":"Clin Med Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.msard.2017.08.016","article-title":"Radiologically isolated syndrome and multiple sclerosis","volume":"17","author":"Yamout","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","article-title":"CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance","volume":"12","author":"Romo-Tena","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13073-019-0652-8","article-title":"Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach","volume":"11","author":"Khan","year":"2019","journal-title":"Genome Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (United Kingdom)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother."},{"key":"B55","volume-title":"Paraneoplastic Syndromes","author":"Darnell","year":"2011"},{"key":"B56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/(SICI)1096-911X(199602)26:2<111::AID-MPO8>3.0.CO;2-O","article-title":"Solitary focal demyelination in the brain as a paraneoplastic disorder","volume":"26","author":"Jaster","year":"1996","journal-title":"Med Pediatr Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00004728-199801000-00026","article-title":"Paraneoplastic demyelinating disorder in the brain of a patient with seminoma","volume":"22","author":"Wong","year":"1998","journal-title":"J Comput Assist Tomogr."},{"key":"B58","first-page":"24","article-title":"Paraneoplastic syndrome simulating encephalitis in the course of testicular seminoma","volume":"35","author":"Ka\u0142uza","year":"1997","journal-title":"Folia Neuropathol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1212\/NXI.0000000000000527","article-title":"Paraneoplastic recurrent tumefactive demyelination in a 62-year-old man with metastatic seminoma","volume":"6","author":"Thebault","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflammation."},{"key":"B60","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int J Cancer."},{"key":"B61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(00)00322-2","article-title":"CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis","volume":"109","author":"Karandikar","year":"2000","journal-title":"J Neuroimmunol."},{"key":"B62","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.155.10.4521","article-title":"CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system","volume":"155","author":"Khoury","year":"1995","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1177\/1352458516662727","article-title":"ACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis","volume":"23","author":"Khoury","year":"2017","journal-title":"Mult Scler J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflammation."},{"key":"B71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and clinical impact of anti-TNF\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.538695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:16:46Z","timestamp":1697314606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.538695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":72,"alternative-id":["10.3389\/fneur.2020.538695"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.538695","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"article-number":"538695"}}